Assessment of changes in immune measures of multiple sclerosis patients treated with laquinimod

Journal of Neuroimmunology

Volumn 263, Issue 1-2, 2013, Pages 108-115

  Lund, Brett T ^a   Kelland, Eve E ^a   Hayardeny, Liat ^b   Barilan, Oren ^b   Gilmore, Wendy ^a   Weiner, Leslie P ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b TEVA PHARMACEUTICALS   (Israel)

Author keywords

Immune measures; Laquinimod; MS oral therapy; PBMC

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; LAQUINIMOD; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CLINICAL ARTICLE; DENDRITIC CELL; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; LONGITUDINAL STUDY; MACROPHAGE; MALE; MONOCYTE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; T LYMPHOCYTE;

IMMUNE MEASURES; LAQUINIMOD; MS ORAL THERAPY; PBMC;

ADULT; COHORT STUDIES; FEMALE; HUMANS; IMMUNOLOGIC SURVEILLANCE; LEUKOCYTES, MONONUCLEAR; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES; QUINOLONES; TREATMENT OUTCOME;

EID: 84884814792     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.07.008     Document Type: Article

References (39)

1. Aharoni R., Saada R., Eilam R., Hayardeny L., Sela M., Arnon R. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2012, 251:14-24.
2. Azoulay D., Vachapova V., Shihman B., Miler A., Karni A. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J. Neuroimmunol. 2005, 167:215-218.
3. Brod S.A., Marshall G.D., Henninger E.M., Sriram S., Khan M., Wolinsky J.S. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis. Neurology 1996, 46:1633-1638.
4. Bruck W., Wegner C. Insight into the mechanism of laquinimod action. J. Neurol. Sci. 2011, 306:173-179.
5. Bruck W., Pfortner R., Pham T., Zhang J., Hayardeny L., Piryatinsky V., Hanisch U.K., Regen T., Van Rossum D., Brakelmann L., Hagemeier K., Kuhlmann T., Stadelmann C., John G.R., Kramann N., Wegner C. Reduced astrocytic NF-kappaB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012, 124:411-424.
6. Brunmark C., Runstrom A., Ohlsson L., Sparre B., Brodin T., Astrom M., Hedlund G. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2002, 130:163-172.
7. Comi G., Pulizzi A., Rovaris M., Abramsky O., Arbizu T., Boiko A., Gold R., Havrdova E., Komoly S., Selmaj K., Sharrack B., Filippi M. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008, 371:2085-2092.
8. Comi G., Abramsky O., Arbizu T., Boyko A., Gold R., Havrdova E., Komoly S., Selmaj K., Sharrack B., Filippi M. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult. Scler. 2010, 16:1360-1366.
9. Comi G., Jeffery D., Kappos L., Montalban X., Boyko A., Rocca M.A., Filippi M. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N. Engl. J. Med. 2012, 366:1000-1009.
10. Dhib-Jalbut S., Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology 2010, 74(Suppl. 1):S17-S24.
11. Dhib-Jalbut S., Chen M., Said A., Zhan M., Johnson K.P., Martin R. Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype. J. Neuroimmunol. 2003, 140:163-171.
12. Duda P.W., Schmied M.C., Cook S.L., Krieger J.I., Hafler D.A. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest. 2000, 105:967-976.
13. Gurevich M., Gritzman T., Orbach R., Tuller T., Feldman A., Achiron A. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study. J. Neuroimmunol. 2010, 221:87-94.
14. Jonsson S., Andersson G., Fex T., Fristedt T., Hedlund G., Jansson K., Abramo L., Fritzson I., Pekarski O., Runstrom A., Sandin H., Thuvesson I., Bjork A. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J. Med. Chem. 2004, 47:2075-2088.
15. Kaye J.F., Blaugrund E. Laquinimod inhibits disease severity in murine collagen induced arthritis. Arthritis Rheum. 2011, 63(Suppl. 10):2091.
16. Kaye J.F., Etzyoni R., Keshet-Katz R., Raymond E., Blaugrund E. Laquinimod inhibits disease severity and progression in mouse models of lupus: alone and in combination with standard of care agents. Arthritis Rheum. 2011, 63(Suppl. 10):560.
17. Lund B.T., Ashikian N., Ta H.Q., Chakryan Y., Manoukian K., Groshen S., Gilmore W., Cheema G.S., Stohl W., Burnett M.E., Ko D., Kachuck N.J., Weiner L.P. Increased CXCL8 (IL-8) expression in multiple sclerosis. J. Neuroimmunol. 2004, 155:161-171.
18. Miller A., Shapiro S., Gershtein R., Kinarty A., Rawashdeh H., Honigman S., Lahat N. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J. Neuroimmunol. 1998, 92:113-121.
19. Mishra M.K., Wang J., Silva C., Mack M., Yong V.W. Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod. Am. J. Pathol. 2012, 181:642-651.
20. Molendijk M.L., Haffmans J.P., Bus B.A., Spinhoven P., Penninx B.W., Prickaerts J., Oude Voshaar R.C., Elzinga B.M. Serum BDNF concentrations show strong seasonal variation and correlations with the amount of ambient sunlight. PLoS One 2012, 7:e48046.
21. Neuhaus O., Strasser-Fuchs S., Fazekas F., Kieseier B.C., Niederwieser G., Hartung H.P., Archelos J.J. Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 2002, 59:990-997.
22. Piccirillo C.A., Thornton A.M. Cornerstone of peripheral tolerance: naturally occurring CD4+CD25+ regulatory T cells. Trends Immunol. 2004, 25:374-380.
23. bright natural killer (NK) cells: an important NK cell subset. Immunology 2009, 126:458-465.
24. Polman C., Barkhof F., Sandberg-Wollheim M., Linde A., Nordle O., Nederman T. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005, 64:987-991.
25. Racke M.K., Lovett-Racke A.E., Karandikar N.J. The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology 2010, 74(Suppl. 1):S25-S30.
26. Reichert T., Debruyere M., Deneys V., Totterman T., Lydyard P., Yuksel F., Chapel H., Jewell D., Van Hove L., Linden J., et al. Lymphocyte subset reference ranges in adult Caucasians. Clin. Immunol. Immunopathol. 1991, 60:190-208.
27. Runstrom A., Leanderson T., Ohlsson L., Axelsson B. Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice. J. Neuroimmunol. 2006, 173:69-78.
28. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
29. Sarchielli P., Greco L., Stipa A., Floridi A., Gallai V. Brain-derived neurotrophic factor in patients with multiple sclerosis. J. Neuroimmunol. 2002, 132:180-188.
30. Schulze-Topphoff U., Shetty A., Varrin-Doyer M., Molnarfi N., Sagan S.A., Sobel R.A., Nelson P.A., Zamvil S.S. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One 2012, 7:e33797.
31. Thone J., Ellrichmann G., Seubert S., Peruga I., Lee D.H., Conrad R., Hayardeny L., Comi G., Wiese S., Linker R.A., Gold R. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am. J. Pathol. 2012, 180:267-274.
32. Tongiorgi E., Sartori A., Baj G., Bratina A., Di Cola F., Zorzon M., Pizzolato G. Altered serum content of brain-derived neurotrophic factor isoforms in multiple sclerosis. J. Neurol. Sci. 2012, 320:161-165.
33. Toubi E., Nussbaum S., Staun-Ram E., Snir A., Melamed D., Hayardeny L., Miller A. Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis. J. Neuroimmunol. 2012, 251:45-54.
34. Vollmer T.L., Soelberg Sorenson P., Arnold DL on Behalf of the Bravo Study Group A placebo-controlled and active comparator phase III trial (BRAVO) for relapsing remitting multiple sclerosis 2011, ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis), Amsterdam, The Netherlands.
35. Weber F., Janovskaja J., Polak T., Poser S., Rieckmann P. Effect of interferon beta on human myelin basic protein-specific T-cell lines: comparison of IFNbeta-1a and IFNbeta-1b. Neurology 1999, 52:1069-1071.
36. Wegner C., Stadelmann C., Pfortner R., Raymond E., Feigelson S., Alon R., Timan B., Hayardeny L., Bruck W. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2010, 227:133-143.
37. Yang J.S., Xu L.Y., Xiao B.G., Hedlund G., Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J. Neuroimmunol. 2004, 156:3-9.
38. Ziegler S.F., Ramsdell F., Alderson M.R. The activation antigen CD69. Stem Cells 1994, 12:456-465.
39. Zou L.P., Abbas N., Volkmann I., Nennesmo I., Levi M., Wahren B., Winblad B., Hedlund G., Zhu J. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology 2002, 42:731-739.